Promising early clinical results have reinvigorated the gene therapy field. After decades of unfulfilled potential, this space is gaining tangible momentum, particularly in addressing the unique challenges encountered in the rare disease space.
Gene Therapy for Rare Disorders Europe is the conference that emerged from extensive discussions devoted to overcoming the clinical, manufacturing, regulatory and commercialization hurdles holding back progress in this field.
Rather than replicating broad academic cell and gene therapy meetings, this conference will explore key questions such as:
- How can you create and demonstrate value in reimbursement and market access strategies?
- How can manufacturing be scaled up from academic to commercial GMP scale robustly and effectively?
- What are the best approaches to navigate the regulatory framework in the gene therapy space?
Join your colleagues to accelerate the progress of the next generation of gene therapies that show improved efficacy, enhanced safety and commercial viability.